CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion

Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space. Experimental Design: T...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 15; no. 7; pp. 2231 - 2237
Main Authors Qin, Xue-Jun, Shi, Huan-Zhong, Deng, Jing-Min, Liang, Qiu-Li, Jiang, Jing, Ye, Zhi-Jian
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 01.04.2009
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space. Experimental Design: The concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed. Results: The concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space. Conclusions: Compared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion.
AbstractList Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space. Experimental Design: The concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed. Results: The concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space. Conclusions: Compared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion.
The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space. The concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed. The concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space. Compared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion.
The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space.PURPOSEThe aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space.The concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed.EXPERIMENTAL DESIGNThe concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed.The concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space.RESULTSThe concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space.Compared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion.CONCLUSIONSCompared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion.
Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space. Experimental Design: The concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed. Results: The concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space. Conclusions: Compared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion.
Author Xue-Jun Qin
Zhi-Jian Ye
Jing-Min Deng
Jing Jiang
Huan-Zhong Shi
Qiu-Li Liang
Author_xml – sequence: 1
  givenname: Xue-Jun
  surname: Qin
  fullname: Qin, Xue-Jun
– sequence: 2
  givenname: Huan-Zhong
  surname: Shi
  fullname: Shi, Huan-Zhong
– sequence: 3
  givenname: Jing-Min
  surname: Deng
  fullname: Deng, Jing-Min
– sequence: 4
  givenname: Qiu-Li
  surname: Liang
  fullname: Liang, Qiu-Li
– sequence: 5
  givenname: Jing
  surname: Jiang
  fullname: Jiang, Jing
– sequence: 6
  givenname: Zhi-Jian
  surname: Ye
  fullname: Ye, Zhi-Jian
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21657140$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/19318474$$D View this record in MEDLINE/PubMed
BookMark eNqFkV1rFDEUhoNU7If-BGVuFG-m5uRjksErGWsrrChLvRNCNnNmN5Kd2SYZpf_eLLut4I1XyYHnDe_Jc05OxmlEQl4CvQSQ-h1QpWsqOLvsumVNdc0aAU_IGUipas4aeVLuD8wpOU_pJ6UggIpn5BRaDloocUZ-dN2CsWqJLs4-p6r7KOrdlHz2v7AMTP6dlrieg81TvK9uqw5DSJUf81R9scGvRzvm6lvAOdpQXQ3DnPw0PidPBxsSvjieF-T7p6vb7qZefL3-3H1Y1E6AyvXQWmUlxUbYXjq5Qs2k1LQXODDNqVIguBhEy22rSm3JHKBaadlCL2jbc35B3hze3cXpbsaUzdYnVxraEac5mUYB1RqggK-O4LzaYm920W9tvDcP_1GA10fAJmfDEO3ofHrkGDSytKGFe3_gXJxSijgY57PNZeccrQ8GqNlbMnsDZm_AFEuGarO3VNLyn_Rjkf_k3h5yG7_e_PYRjSv9MEZMaKPbGJBGGcY48D9CZ6Bq
CODEN CCREF4
CitedBy_id crossref_primary_10_1164_rccm_201207_1307OC
crossref_primary_10_4049_jimmunol_0903846
crossref_primary_10_1089_mab_2015_0039
crossref_primary_10_3389_fimmu_2019_02453
crossref_primary_10_1080_15563650_2021_1945081
crossref_primary_10_3389_fcell_2022_816927
crossref_primary_10_1038_s41598_024_75750_1
crossref_primary_10_1080_2162402X_2015_1030561
crossref_primary_10_1158_0008_5472_CAN_11_0952
crossref_primary_10_1186_1471_2407_13_324
crossref_primary_10_1164_rccm_201203_0465PP
crossref_primary_10_1186_s12935_024_03211_w
crossref_primary_10_1016_j_ejca_2011_03_026
crossref_primary_10_1371_journal_pone_0076379
crossref_primary_10_3892_or_2014_3576
crossref_primary_10_4110_in_2009_9_6_209
crossref_primary_10_1158_1535_7163_MCT_14_0448
crossref_primary_10_1159_000362332
crossref_primary_10_1164_rccm_201401_0140ED
crossref_primary_10_1111_j_1365_2559_2011_04040_x
crossref_primary_10_1007_s00262_011_1059_6
crossref_primary_10_4049_jimmunol_1001728
crossref_primary_10_1016_j_jconrel_2015_08_014
crossref_primary_10_1159_000447687
crossref_primary_10_3109_08830185_2010_508854
crossref_primary_10_1016_j_imbio_2014_11_007
crossref_primary_10_1097_IGC_0b013e3182289ab1
crossref_primary_10_1002_hed_21581
crossref_primary_10_1371_journal_pone_0251233
crossref_primary_10_3390_ijms21218412
crossref_primary_10_3389_fimmu_2023_1161375
crossref_primary_10_4049_jimmunol_1400567
crossref_primary_10_1097_MOT_0000000000000130
crossref_primary_10_1016_j_intimp_2023_111332
crossref_primary_10_1111_j_1440_1843_2010_01890_x
crossref_primary_10_1039_D1BM00971K
crossref_primary_10_1038_s41420_023_01312_5
crossref_primary_10_1080_2162402X_2018_1554969
crossref_primary_10_1016_j_canlet_2020_12_016
crossref_primary_10_1371_journal_pone_0040450
crossref_primary_10_1002_ctm2_1356
crossref_primary_10_1038_s41598_018_35840_3
crossref_primary_10_3389_fonc_2021_672747
crossref_primary_10_1155_2011_865684
crossref_primary_10_1586_era_12_153
crossref_primary_10_1172_JCI43048
crossref_primary_10_1038_onc_2016_458
crossref_primary_10_1111_imr_12761
crossref_primary_10_1016_j_jss_2016_11_067
crossref_primary_10_3389_fimmu_2021_760683
crossref_primary_10_1016_j_pharmthera_2009_12_003
crossref_primary_10_1016_j_yexcr_2022_113212
crossref_primary_10_1038_s42003_022_04356_y
crossref_primary_10_1016_j_canlet_2012_07_013
crossref_primary_10_1007_s11596_013_1066_2
crossref_primary_10_1111_crj_12351
crossref_primary_10_4161_onci_26836
crossref_primary_10_1038_s41417_023_00678_z
crossref_primary_10_1155_2014_730380
crossref_primary_10_1186_s12967_015_0618_6
crossref_primary_10_1186_1465_9921_12_77
crossref_primary_10_1158_2326_6066_CIR_13_0028
crossref_primary_10_1158_0008_5472_CAN_11_0573
crossref_primary_10_5507_bp_2016_062
crossref_primary_10_1016_j_it_2014_07_004
crossref_primary_10_3390_ijms21165647
crossref_primary_10_1016_j_canlet_2019_03_040
Cites_doi 10.4049/jimmunol.172.9.5213
10.1038/nm1093
10.1158/1078-0432.CCR-04-0371
10.1016/j.clim.2006.10.014
10.1084/jem.194.6.847
10.1038/ni1180
10.1002/ijc.23392
10.1093/intimm/dxm014
10.1038/nri821
10.1182/blood-2005-02-0642
10.1183/09031936.93.01040337
10.1093/jnci/djm064
10.1164/rccm.200504-588OC
10.1158/1078-0432.CCR-03-0239
10.1182/blood-2006-02-002774
10.1016/j.humimm.2005.11.005
10.1164/ajrccm.162.5.ats8-00
10.1378/chest.06-1757
10.1097/01.mcp.0000166490.92659.17
10.1378/chest.103.6.1732
10.4049/jimmunol.177.7.4488
10.1056/NEJMcp010731
10.1097/00029330-200804010-00001
10.1158/0008-5472.CAN-06-0261
10.4049/jimmunol.168.9.4272
10.1183/09031936.05.00090804
ContentType Journal Article
Copyright 2009 INIST-CNRS
Copyright_xml – notice: 2009 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1158/1078-0432.CCR-08-2641
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 2237
ExternalDocumentID 19318474
21657140
10_1158_1078_0432_CCR_08_2641
15_7_2231
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
29B
2WC
34G
39C
3O-
4H-
53G
55
5GY
5RE
5VS
AAPBV
ABFLS
ABOCM
ACIWK
ACPRK
ADACO
ADBBV
ADBIT
AENEX
AETEA
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C1A
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FH7
FRP
GX1
H13
H~9
IH2
KQ8
L7B
LSO
MVM
O0-
OHT
OK1
P0W
P2P
RCR
RHF
RHI
RNS
SJN
UDS
VH1
W2D
WOQ
X7M
XFK
XJT
ZA5
ZCG
---
.55
18M
2FS
6J9
AAFWJ
AAJMC
AAYXX
ACGFO
ACSVP
ADCOW
AFHIN
AFOSN
AFUMD
AI.
BR6
BTFSW
CITATION
QTD
TR2
W8F
YKV
.GJ
1CY
ADNWM
IQODW
J5H
WHG
ZGI
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c417t-f9a7a50e64ad5c5be825580d4ef2830771434f493a9718452c1e7b8591d409d33
ISSN 1078-0432
IngestDate Fri Jul 11 00:57:35 EDT 2025
Thu Apr 03 06:57:25 EDT 2025
Mon Jul 21 09:13:39 EDT 2025
Tue Jul 01 03:06:20 EDT 2025
Thu Apr 24 23:03:38 EDT 2025
Fri Jan 15 19:22:03 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords CD4 T lymphocyte
T-Lymphocyte
Pleural disease
Malignant tumor
Malignant pleural effusion
Regulatory cell
Cancer
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c417t-f9a7a50e64ad5c5be825580d4ef2830771434f493a9718452c1e7b8591d409d33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://aacrjournals.org/clincancerres/article-pdf/15/7/2231/1987917/2231.pdf
PMID 19318474
PQID 67108811
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_67108811
pubmed_primary_19318474
pascalfrancis_primary_21657140
crossref_citationtrail_10_1158_1078_0432_CCR_08_2641
crossref_primary_10_1158_1078_0432_CCR_08_2641
highwire_cancerresearch_15_7_2231
ProviderPackageCode RHF
RHI
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-04-01
PublicationDateYYYYMMDD 2009-04-01
PublicationDate_xml – month: 04
  year: 2009
  text: 2009-04-01
  day: 01
PublicationDecade 2000
PublicationPlace Philadelphia, PA
PublicationPlace_xml – name: Philadelphia, PA
– name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2009
Publisher American Association for Cancer Research
Publisher_xml – name: American Association for Cancer Research
References 2022061022335836200_B17
2022061022335836200_B18
2022061022335836200_B15
2022061022335836200_B16
2022061022335836200_B19
2022061022335836200_B10
2022061022335836200_B1
2022061022335836200_B13
2022061022335836200_B14
2022061022335836200_B3
2022061022335836200_B11
2022061022335836200_B2
2022061022335836200_B12
2022061022335836200_B5
2022061022335836200_B4
2022061022335836200_B7
2022061022335836200_B6
2022061022335836200_B9
2022061022335836200_B8
2022061022335836200_B28
2022061022335836200_B26
2022061022335836200_B27
2022061022335836200_B20
2022061022335836200_B21
2022061022335836200_B24
2022061022335836200_B25
2022061022335836200_B22
2022061022335836200_B23
References_xml – ident: 2022061022335836200_B18
  doi: 10.4049/jimmunol.172.9.5213
– ident: 2022061022335836200_B22
  doi: 10.1038/nm1093
– ident: 2022061022335836200_B28
  doi: 10.1158/1078-0432.CCR-04-0371
– ident: 2022061022335836200_B19
  doi: 10.1016/j.clim.2006.10.014
– ident: 2022061022335836200_B25
  doi: 10.1084/jem.194.6.847
– ident: 2022061022335836200_B27
– ident: 2022061022335836200_B5
  doi: 10.1038/ni1180
– ident: 2022061022335836200_B11
  doi: 10.1002/ijc.23392
– ident: 2022061022335836200_B20
  doi: 10.1093/intimm/dxm014
– ident: 2022061022335836200_B4
  doi: 10.1038/nri821
– ident: 2022061022335836200_B7
– ident: 2022061022335836200_B13
  doi: 10.1182/blood-2005-02-0642
– ident: 2022061022335836200_B16
  doi: 10.1183/09031936.93.01040337
– ident: 2022061022335836200_B21
  doi: 10.1093/jnci/djm064
– ident: 2022061022335836200_B10
  doi: 10.1164/rccm.200504-588OC
– ident: 2022061022335836200_B12
  doi: 10.1158/1078-0432.CCR-03-0239
– ident: 2022061022335836200_B6
  doi: 10.1182/blood-2006-02-002774
– ident: 2022061022335836200_B9
  doi: 10.1016/j.humimm.2005.11.005
– ident: 2022061022335836200_B14
  doi: 10.1164/ajrccm.162.5.ats8-00
– ident: 2022061022335836200_B15
  doi: 10.1378/chest.06-1757
– ident: 2022061022335836200_B2
  doi: 10.1097/01.mcp.0000166490.92659.17
– ident: 2022061022335836200_B17
  doi: 10.1378/chest.103.6.1732
– ident: 2022061022335836200_B26
  doi: 10.4049/jimmunol.177.7.4488
– ident: 2022061022335836200_B1
  doi: 10.1056/NEJMcp010731
– ident: 2022061022335836200_B3
  doi: 10.1097/00029330-200804010-00001
– ident: 2022061022335836200_B24
  doi: 10.1158/0008-5472.CAN-06-0261
– ident: 2022061022335836200_B8
  doi: 10.4049/jimmunol.168.9.4272
– ident: 2022061022335836200_B23
  doi: 10.1183/09031936.05.00090804
SSID ssj0014104
Score 2.2333102
Snippet Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of...
Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of...
The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these...
SourceID proquest
pubmed
pascalfrancis
crossref
highwire
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2231
SubjectTerms Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Chemokine CCL17 - analysis
Chemokine CCL22 - metabolism
Chemokine CCL22 - pharmacology
Chemokine CCL22 - physiology
Chemotaxis
Humans
Interleukin-2 Receptor alpha Subunit - analysis
lung cancer
malignant pleural effusion
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pleural Effusion, Malignant - immunology
regulatory T cells
T-Lymphocytes, Regulatory - immunology
Title CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion
URI http://clincancerres.aacrjournals.org/content/15/7/2231.abstract
https://www.ncbi.nlm.nih.gov/pubmed/19318474
https://www.proquest.com/docview/67108811
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAvaHyXwTASb1VK4thN8oiyoTFaBKWTKoRk5cPZKpVsWhse-Mf497iznS8YYvASNVGdnvr7-Xx3Pt8R8hIcnNDzsshRLGAOT3If5pwXOZPcVV4eJjws0FGcvZ8cnfDjpVgOBj86WUvVNh1n3688V_I_qMIzwBVPyf4Dss1L4QF8BnzhCgjD9VoYx_GUMW35VRj_jw-4Y5Kwvim4YaK9m5uW87ihvhjFar3GNCwwO2dghp9iLszow1rpChyHRVFtarDqEgb18ckMOXI5shWCmkjyslLOcVWOPq7KliZJ6Xw-w05Gn85WTZ4OLJTObFWCmrMrJsZcV5UzXY2mQNTTXhAi6uSutHn_oJA6nNJpkrERa94VyyhaFyv7chvbVFb5ClB4zPSOaLSz6LAw6KpaZpaP39cAEepwhP2BcRzPMQgMll_v-wDlxVdNDLBhwc81zYL6Fbl_WSmb_EVPyECiADfITQb-CbbOOHj7rtm-4p7uW9nIYI-OgWSvrpRLl641QvTto7pmNabsJhsAujDtVv7sD2m7aLFL7liHhr427LxLBqq8R27NbMrGffJFk5TWJKVdktIeSWlLUrqgmqQUSUobklJLUlqT9AE5eXO4iI8c29LDybgXbJ0iSoJEuGoCWkFkIlUhuLShm3NVYCW6IADznRc88pMIjCYuWOapIMUaizl3o9z3H5Kd8rxUjwn1fZV4XClYsV2eF3nqgy2mchjHeCFYOiS8_iNlZuvdY9uVtdR-rwglQiERCglQSDeUCMWQjJthF6bgy98GvKhRkmYW1pNQNjQZkv0efM2bmTcRWDJzSJ7XeErQ77hpl5TqvNrICbgAIajTIXlkYG6lsox5cg0B9sjtdto-JTvby0o9A2t6m-5r5v4Ef9HBrA
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CCL22+Recruits+CD4-positive+CD25-positive+Regulatory+T+Cells+into+Malignant+Pleural+Effusion&rft.jtitle=Clinical+cancer+research&rft.au=Xue-Jun+Qin&rft.au=Huan-Zhong+Shi&rft.au=Jing-Min+Deng&rft.au=Qiu-Li+Liang&rft.date=2009-04-01&rft.pub=American+Association+for+Cancer+Research&rft.issn=1078-0432&rft.eissn=1557-3265&rft.volume=15&rft.issue=7&rft.spage=2231&rft_id=info:doi/10.1158%2F1078-0432.CCR-08-2641&rft_id=info%3Apmid%2F19318474&rft.externalDBID=n%2Fa&rft.externalDocID=15_7_2231
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon